McKesson Corporation's March 2024 Pharmaceutical Prime Vendor contract with VA totaled over $851 million

Contract Overview

Contract Amount: $851,413,499 ($851.4M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2024-03-01

End Date: 2024-03-31

Contract Duration: 30 days

Daily Burn Rate: $28.4M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 MARCH

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $851.4 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 MARCH Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending, highlighting the critical role of prime vendors. 2. Analysis of value for money requires benchmarking against historical pricing and other federal pharmaceutical contracts. 3. Competition dynamics for prime vendor contracts are crucial for ensuring competitive pricing and efficient distribution. 4. Risk indicators may include supply chain disruptions, price volatility, and contractor performance. 5. Performance context is essential, evaluating McKesson's ability to meet delivery timelines and product availability. 6. Sector positioning shows this contract within the broader healthcare and pharmaceutical distribution market.

Value Assessment

Rating: good

This contract's value is substantial, reflecting the scale of the Department of Veterans Affairs' pharmaceutical needs. Benchmarking against similar prime vendor contracts, particularly those awarded by other large federal agencies like the Department of Defense, would provide a clearer picture of value for money. While the firm-fixed-price structure offers cost certainty, ongoing monitoring of unit prices against market trends is advisable to ensure continued cost-effectiveness.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple bidders had the opportunity to submit proposals. This competitive process is designed to foster price discovery and ensure the government receives the best value. The number of bidders and the evaluation criteria used would further inform the assessment of competition effectiveness.

Taxpayer Impact: Full and open competition generally leads to more favorable pricing for taxpayers by encouraging a wider range of suppliers to offer their best terms.

Public Impact

Veterans across the nation benefit from timely access to essential pharmaceuticals. The contract ensures the supply of a wide range of pharmaceutical preparations to VA medical facilities. Geographic impact is nationwide, supporting healthcare delivery to veterans in all states. Workforce implications include support for logistics, warehousing, and administrative roles within the pharmaceutical supply chain.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases on specific drugs over time.
Dependence on a single prime vendor could create supply chain vulnerabilities.
Ensuring consistent quality and availability of all required pharmaceuticals.

Positive Signals

Established track record of McKesson Corporation in pharmaceutical distribution.
Firm-fixed-price contract provides cost predictability.
Full and open competition suggests a competitive award process.

Sector Analysis

The pharmaceutical prime vendor (PPV) program is a critical component of the federal government's strategy to procure and distribute medications efficiently. This contract with McKesson Corporation falls within the broader healthcare and pharmaceutical distribution sector, a market characterized by complex supply chains, regulatory oversight, and significant economies of scale. Comparable spending benchmarks would involve analyzing the total federal outlays for pharmaceuticals and the market share of major distributors like McKesson within the government sector.

Small Business Impact

Analysis of small business set-aside implications is not directly applicable as this contract was awarded under full and open competition. However, the prime vendor's subcontracting plan, if any, could offer opportunities for small businesses to participate in the pharmaceutical supply chain. The impact on the small business ecosystem would depend on the extent to which McKesson engages small businesses for logistics, warehousing, or specialized services.

Oversight & Accountability

Oversight for this contract is primarily managed by the Department of Veterans Affairs contracting officers and program managers. Accountability measures are embedded in the contract terms, including performance standards and delivery requirements. Transparency is facilitated through contract award databases and reporting requirements. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse.

Related Government Programs

Federal Supply Schedule (FSS) contracts for pharmaceuticals
Department of Defense pharmaceutical procurement
Other agency prime vendor contracts

Risk Flags

Potential for drug shortages
Price fluctuations in pharmaceutical market
Supply chain integrity risks
Contractor performance variability

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $851.4 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 MARCH

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $851.4 million.

What is the period of performance?

Start: 2024-03-01. End: 2024-03-31.

What is McKesson Corporation's historical performance record with the VA for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs as a pharmaceutical prime vendor. Historical performance data, typically found in contract performance reports and past performance evaluations, would detail their reliability in terms of on-time delivery, order fill rates, and product availability. While specific metrics for this exact delivery order are not detailed here, McKesson's general track record in large-scale pharmaceutical distribution suggests a capacity to manage complex logistical requirements. However, a thorough review would involve examining any past performance issues, corrective actions, or commendations received across their various VA contracts to fully assess their suitability and reliability for this critical service.

How does the pricing in this delivery order compare to similar pharmaceutical prime vendor contracts awarded by other federal agencies?

Direct comparison of pricing for this specific $851 million delivery order to other federal agencies' prime vendor contracts is challenging without access to detailed pricing structures and product-specific data. However, the firm-fixed-price (FFP) contract type suggests that pricing was established at the time of award and is intended to remain stable. To assess value, one would benchmark the aggregate cost of pharmaceuticals procured under this order against FSS pricing, other agency contracts, or even commercial market rates for similar volumes and services. Factors like contract duration, specific product mix, and negotiated discounts significantly influence price comparisons, making a precise benchmark difficult without more granular data.

What are the primary risk indicators associated with this pharmaceutical prime vendor contract?

Key risk indicators for this pharmaceutical prime vendor contract include potential supply chain disruptions, which could arise from manufacturing issues, transportation problems, or geopolitical events affecting drug availability. Price volatility for specific pharmaceuticals, despite the FFP structure, can pose a risk if market prices deviate significantly from negotiated rates, impacting the VA's budget. Contractor performance risk is also present, encompassing McKesson's ability to consistently meet delivery schedules, maintain adequate inventory levels, and ensure the quality and integrity of the pharmaceuticals supplied. Furthermore, cybersecurity risks related to the handling of sensitive pharmaceutical data and operational technology are increasingly relevant.

How effective is the VA's current pharmaceutical procurement strategy in ensuring access to essential medicines for veterans?

The VA's pharmaceutical procurement strategy, which includes the use of prime vendors like McKesson, is generally considered effective in ensuring broad access to essential medicines for veterans nationwide. The prime vendor model centralizes procurement and distribution, leveraging economies of scale to potentially reduce costs and streamline logistics. The VA's formulary system and robust contracting processes aim to secure necessary medications at competitive prices. However, effectiveness can be measured by metrics such as fill rates, delivery timeliness, and the availability of drugs on the VA's formulary. Continuous evaluation and adaptation of the strategy are necessary to address emerging challenges like drug shortages, price inflation, and the introduction of new, high-cost therapies.

What are the historical spending patterns for pharmaceutical prime vendor services by the Department of Veterans Affairs?

Historical spending patterns for pharmaceutical prime vendor services by the Department of Veterans Affairs show a consistent and significant investment in ensuring medication availability for veterans. Over the years, the VA has relied on prime vendors to manage a substantial portion of its pharmaceutical needs due to the complexity and scale involved. Annual spending has typically been in the hundreds of millions, if not billions, of dollars, reflecting the large veteran population and the wide range of medications required. This spending has generally trended upwards, influenced by factors such as an aging veteran population, advancements in medical treatments, and fluctuations in drug prices. The VA's commitment to the prime vendor model underscores its strategic importance in their overall healthcare supply chain management.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $851,413,499

Exercised Options: $851,413,499

Current Obligation: $851,413,499

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline